Anya Schiess

Managing Partner, Life Sciences Private Capital (VC)

San Francisco, California

2022

Co-Managing Partner, Healthcare Private Capital (venture capital)
2022
J.P. Morgan is launching a new healthcare venture capital effort. We will invest in healthcare companies across multiple strategies aligned to specific market opportunities. Our early-stage fund will focus on novel therapeutics and technologies in several target areas including Genetic Medicine, Oncology, Neurodegenerative Disease, Rare Diseases, Autoimmunity, AI/ML platforms, Metabolic Diseases and Neuropsychology. Our venture growth stage opportunities across the healthcare spectrum, focused on treatments and technologies that save and improve patients' lives.

2020

2015 - 2022

Founder, General Partner
2015 - 2022
Co-founded Firm in 2015. Early stage healthcare fund focusing on technology infrastructure companies in healthcare and life sciences. Lead investor and board director in over 20 companies.

2008 - 2014

Venture Capital
2008 - 2014
Thomas, McNerney is a life-science focused fund with $600M under management, across two funds. At Thomas, McNerney, I participated in the deals in the biopharmaceutical, medical device, and diagnostics industries, including leading the seed-stage investment and follow-ons in InVitae (fka Locus Development). I held board or observer seats in: Virdante Pharmaceuticals, InVitae (NASDAQ: NVTA), Celator Pharmaceuticals (NASDAQ: CPXX) , InnoPharma (acquired by Pfizer).

2004 - 2008

Sales and Marketing Managment positions
2004 - 2008
Medtronic is the leading global medical device company. I held several management positions in the marketing and then sales organization. In Europe, I helped build the obesity business then managed the cardiac stent team, including launching 3 stents (2 follow-on drug eluting stents and one new bare metal stent). In the US, I led the service team (clinical specialists) within the sales organization, based in Chicago, IL.

2003 - 2004